Free Trial
NASDAQ:ANEB

Anebulo Pharmaceuticals Q4 2023 Earnings Report

Anebulo Pharmaceuticals logo
$2.52 -0.09 (-3.45%)
Closing price 08/28/2025 03:57 PM Eastern
Extended Trading
$2.52 +0.00 (+0.20%)
As of 08/28/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anebulo Pharmaceuticals EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.10
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Anebulo Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anebulo Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, September 20, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Anebulo Pharmaceuticals' Q4 2025 earnings is scheduled for Wednesday, September 24, 2025, with a conference call scheduled on Monday, September 22, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Anebulo Pharmaceuticals Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
See More Anebulo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anebulo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anebulo Pharmaceuticals and other key companies, straight to your email.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals (NASDAQ:ANEB), a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

View Anebulo Pharmaceuticals Profile

More Earnings Resources from MarketBeat